Navigation Links
Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
Date:12/7/2010

ults to be an indication of our future performance. For a discussion of the risk factors and other factors that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our annual report on Form 10-K and quarterly reports on Form 10-Q.  We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management's expectations or otherwise, except as may be required by law.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Sept. 22, 2014 The western European ... It is largely a replacement market with fewer ... mergers, acquisitions and partnerships are redefining competitive landscape ... research service provides details about revenue forecasts, unit ... trends across the country. The changing landscape makes ...
(Date:9/22/2014)... , September 22, 2014 ... September 25   The second edition of ... are excited to announce the final nominations for the ... announced on the evening of September 25 at The Taj Mahal Palace, ... from applicants based on a variety of qualitative and ...
(Date:9/22/2014)... , Sept. 22, 2014  Elusys Therapeutics, Inc. ... treat infectious disease, today announced it has completed ... of obiltoxaximab (ETI-204). Obiltoxaximab is an anti-toxin in ... data from these studies support the safety and ... at the intended therapeutic dose. The conclusion of ...
Breaking Medicine Technology:Automated Endoscope Reprocessor Market Trends in Western Europe 2Automated Endoscope Reprocessor Market Trends in Western Europe 3Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 2Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6
... Inc. (Nasdaq: JAZZ ) today announced that it ... November 1, 2011 at 4:30 p.m. Eastern Time/1:30 p.m. Pacific ... and financial update and review third quarter 2011 results.   ... accessed from the Investors section of the Jazz Pharmaceuticals, website ...
... N.Y., Oct. 20, 2011 The Virginia Dental ... social responsibility program of Henry Schein, Inc. (NASDAQ: ... health care products and services to office-based practitioners, ... the recent American Dental Association (ADA) Annual Meeting ...
Cached Medicine Technology:The Virginia Dental Association Honors Henry Schein Cares With the Organization's First Corporate Partner Award 2The Virginia Dental Association Honors Henry Schein Cares With the Organization's First Corporate Partner Award 3
(Date:9/23/2014)... driving force behind many chronic diseases, especially liver ... caused by conditions such as viral hepatitis or ... Now, scientists at Virginia Commonwealth University Massey Cancer ... preclinical studies that blocking the expression of a ... the development and progression of liver cancer by ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Becker's ... its list of "125 Hospitals and Health Systems ... health systems featured on the list have orthopedic ... earned recognition from several reputable sources. Exceptional orthopedic ... patients, front-line orthopedic research and treat professional athletes. ...
(Date:9/23/2014)... 2014 The "area under the curve of oxygen ... approach to monitoring blood oxygen levels during procedures using ... & Analgesia . , The AUC Desat provides ... lowbut also on the depth, duration, and rate of ... Paul Niklewski, PhD, of University of Cincinnati and colleagues ...
(Date:9/23/2014)... Contrary to what is often assumed about single parents, ... from The Kinsey Institute has found that single parents ... active as often as singles without children -- and ... The study, "Dating and Sexual Behavior Among Single Parents ... online in the Journal of Sex Research ...
(Date:9/23/2014)... September 23, 2014 Kenall Manufacturing, ... expanded its MedMaster™ M4 product line with a ... the M4 product line – currently available with ... – providing more flexibility when designing lighting for ... MedMaster M4 Series include:, •Three sizes available ...
Breaking Medicine News(10 mins):Health News:Study uncovers genetic driver of inflammation, uses it to prevent and treat liver cancer 2Health News:125 Hospitals With Great Orthopedic Programs 2Health News:125 Hospitals With Great Orthopedic Programs 3Health News:125 Hospitals With Great Orthopedic Programs 4Health News:125 Hospitals With Great Orthopedic Programs 5Health News:New measure provides more data on oxygen levels during sedation 2Health News:Kinsey study of single parents' dating, sexual activity contradicts assumptions 2Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 2Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 3
... don,t let love interfere with your work, researchers say , ... who found your Valentine at work, here,s good news. , ... negative effect, a new Canadian study finds. , "Most people ... they don,t affect productivity, de-motivate other colleagues or have an ...
... ... Toppers feature 100% Natural Dunlop Latex for an affordable 100% natural latex mattress or ... organic Eco Wool batting, creating an organic latex mattress, free from chemical fire-retardants. ... (PRWEB) February 14, ...
... ... practitioner now seeing patients in the River Walk Medical Arts Building. , ... (PRWEB) February 14, 2010 -- Elias Medical recently ... office is located within the River Walk Medical Arts Building at 9900 Stockdale Highway, adjacent ...
... , LOS ANGELES , ... today by Consumer Watchdog -- Anthem Blue Cross,s announcement today that ... or more should not deter the California Legislature from taking immediate ... Other California health insurers -- including Blue Shield of ...
... Feb. 13 The beauty of budding plants and ... allergy sufferers, though, gardening can be as much a chore as ... cause an onslaught of allergy symptoms, including sneezing, itchy eyes, congestion ... can take a few simple steps to minimize their risk of ...
... Compassion appeared to be contagious in experiment using volunteers ... do a good deed appears to inspire you to do ... , In an experiment, researchers recruited volunteers who watched a ... a clip from "The Oprah Winfrey Show" in which musicians ...
Cached Medicine News:Health News:Office Romance OK With Most Folks 2Health News:Foamsource Introduces Natural Slumber 100% Natural Latex Mattresses & Toppers with Free Shipping 2Health News:Foamsource Introduces Natural Slumber 100% Natural Latex Mattresses & Toppers with Free Shipping 3Health News:Elias Medical Announces Move to New Stockdale Highway Practice 2Health News:Anthem Blue Cross's Announcement That It Will Temporarily Suspend a 39% Health Insurance Rate Increase Should Not Deter Immediate Legislative Action 2Health News:Avoid Allergens to Reap the Rewards of Gardening 2Health News:Avoid Allergens to Reap the Rewards of Gardening 3Health News:Witnessing Uplifting Behavior May Spur Good Deeds 2
Provides a combination of concentrated cold / hot and compression for the wrist...
Provides a combination of concentrated cold / hot and compression for the shoulder...
Provides extended cold therapy to the knee area for acute, chronic, or post-surgical applications. Cryotherapy can reduce pain, swelling and facilitate faster rehabilitation....
... The Philly® One-Piece™ Collar is completely ... padding and features our patented chin support. ... flat, storage is efficiently managed where space ... ensure easy recognition of sizes., ,Either ...
Medicine Products: